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Abstract: Exercise-induced increases in pulmonary blood flow normally increase pulmonary arterial
pressure only minimally, largely due to a reserve of pulmonary capillaries that are available for
recruitment to carry the flow. In pulmonary arterial hypertension, due to precapillary arteriolar
obstruction, such recruitment is greatly reduced. In exercising pulmonary arterial hypertension
patients, pulmonary arterial pressure remains high and may even increase further. Current pulmonary
arterial hypertension therapies, acting principally as vasodilators, decrease calculated pulmonary
vascular resistance by increasing pulmonary blood flow but have a minimal effect in lowering
pulmonary arterial pressure and do not restore significant capillary recruitment. Novel pulmonary
arterial hypertension therapies that have mainly antiproliferative properties are being developed to
try and diminish proliferative cellular obstruction in precapillary arterioles. If effective, those agents
should restore capillary recruitment and, during exercise testing, pulmonary arterial pressure should
remain low despite increasing pulmonary blood flow. The effectiveness of every novel therapy for
pulmonary arterial hypertension should be evaluated not only at rest, but with measurement of
exercise pulmonary hemodynamics during clinical trials.
Keywords: pulmonary arterial hypertension; hemodynamics; exercise; pulmonary hypertension
therapy; pulmonary microvasculature; pulmonary capillary; pulmonary vascular resistance
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Normal human pulmonary circulation has the remarkable ability to accept major
increases in blood flow with only minor rises in pulmonary artery pressure, best exemplified
by the hemodynamic response to exercise [1–4]. The lungs have an extremely large capillary
surface area, equivalent to approximately two tennis courts in an adult. However, at
rest, only a fraction of that surface area is being perfused, with a large number of nonconcomitantly perfused capillaries available for low driving pressure-recruitment as the
demand for accommodation of cardiac output increases [5–8]. As an example, one need
only observe water finding an expanding surface area on a tabletop to understand that a
high driving pressure is not required to optimize the surface area utilized. As blood flow
continues to rise, maximal regional recruitment is attained, and any further increases in
flow result in distention of already perfused capillaries.
The development of techniques to measure the first-pass transpulmonary metabolism
of radio-labelled peptides has enabled the identification and analysis of the recruitment
and distention phases of capillary blood flow [9]. The pulmonary endothelial luminal
surface is the major site of angiotensin-1 ectoenzyme (ACE-1) activity, and the degree
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Pulmonary arterial hypertension is a devastating group of disorders in which progressive structural remodeling and luminal obliteration of upstream pulmonary arterioles
cause a heterogenous reduction in perfused downstream capillary surface area [18,19]. By
the time patients present at a pulmonary hypertension clinic with World Health Organization functional class III dyspnea, their perfused capillary surface area at rest may be
30% of normal [14]. The progressive rise in pulmonary arterial pressure causes right heart
failure, reduced cardiac output and ultimately death [20]. The heterogeneous histologic
abnormalities result in acinar capillaries that are fed by less affected arterioles carrying
normal or supernormal flow to support the cardiac output, while flow is extremely reduced
or absent in capillaries downstream from more affected arterioles [21]. Although cardiac
output and thus pulmonary blood flow in these sick patients may be extremely low, it
is possible that even that decreased blood flow results in complete capillary recruitment,
and even distention, in the reduced number of perfused capillaries available to carry it
(Figure 1).
The presently approved mainstays of pulmonary arterial hypertension therapy involve
rebalancing abnormalities in the prostacyclin, nitric oxide and endothelin-1 pathways [22].
These “vasodilator” treatments have provided significant benefit to patients, but are not
curative, and there is no evidence of significant impact on the arteriolar obstruction in
humans even after years of therapy [23]. Although the medications lower calculated
pulmonary vascular resistance mainly via increased cardiac output, some patients may
have a larger decrease in pulmonary arterial pressure [24] and most patients have only a
small improvement, even with prolonged therapy [25,26]. An increased cardiac output can
only be beneficial in a pulmonary arterial hypertension patient, and a decrease in calculated
resting pulmonary vascular resistance has been used as the primary endpoint in the phase
2 studies that contributed to the clinical approval of the majority of our current pulmonary
arterial hypertension therapies. However, in most patients, the question remains: does that
reduction in resting pulmonary vascular resistance represent a gain in perfused capillary
surface area, which would indicate a true restoration of lung circulatory function [27]? The
analysis below suggests not.
Insights can be gained from observations during acute vasodilator studies in patients with idiopathic pulmonary arterial hypertension that have identified two types of
hemodynamic response [28]. These two different responses likely represent two different
pathologies, and studies suggest a different genetic basis [29–31]. The more common “resistance” response is as described above (i.e., increased resting cardiac output with minimal
or no reduction in pulmonary artery pressure, and decreased resting pulmonary vascular
resistance). In a second group, termed “pressure” responders, resting pulmonary vascular
resistance falls, but pulmonary artery pressure falls importantly even as resting cardiac
output increases. However, although decreased resting pulmonary vascular resistance does
help patients clinically, it alone is unable to distinguish between the two groups [27].
Moreover, the responses of the two aforementioned groups to the vasodilator, in terms
of change in capillary surface area, are completely different. When we explore relationships
in the raw data of a previous vasodilator study, the differences between the two groups
are apparent [32]. The “resistance” responders only increased capillary surface area by a
mean of 7% [32]. When the results are viewed in terms of the final functional capillary
surface area attained, versus the final hemodynamic levels attained, it is evident that none
of the “resistance” responders achieved functional capillary surface area levels anywhere
approaching those of the “pressure” responders, who attained the expected normal levels
of functional capillary surface area (Figure 2).
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Figure 2. Functional capillary surface area normalized to body surface area (FCSA, mL/min/m2 )
Figure 2. Functional capillary surface area normalized to body surface area (FCSA, mL/min/m2) in
in human lungs post acute vasodilator therapy, as compared to pulmonary artery pressure (PAP),
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to their downstream capillaries, and they were not able to recruit additional capillary
surface area.
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variety of ventilatory parameters, including ventilatory dead space indicative of ventilation/perfusion matching, are abnormal, and the pulmonary artery pressure/blood flow
slope is abnormally steep. The capillary surface area response to exercise is also abnormal
in pulmonary arterial hypertension (Figure 4). In a small number of such patients who
performed symptom-limited exercise, we have not seen an increase in functional capillary
surface area, showing a lack of recruitment. This has also been detected indirectly by others,
in that patients with pulmonary arterial hypertension have an abnormally high ventilatory
dead space [35].
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will improve exercise hemodynamics without first demonstrating a marked improvement
in resting mean pulmonary artery pressure, as is discussed above. The threshold for that
resting pressure is unknown, but is likely 30 mm Hg or less with a normal cardiac output.
Future studies should search for this threshold and correlate it to normalization of the
exercise response.
Conclusions: Improvement in pulmonary vascular resistance has been an important
endpoint in many clinical studies, and its value has been proven in terms of clinical outcomes and prognosis [43]. However, the use of a reduction in pulmonary vascular resistance
as an indicator of therapeutic success, when it is driven mainly by increased cardiac output
rather than by large decreases in pulmonary arterial pressure, may be misleading with
regard to a medication’s ability to reverse cellular pulmonary microvascular obstruction
and to restore capillary recruitment. The metabolic analysis of pulmonary capillary surface
area is an extremely powerful research tool to aid in the understanding of physiological
microcirculatory function in health and disease [12]. However, it is technically complex
and involves the injection of a radiolabelled peptide, and will therefore be difficult to use
broadly as a clinical tool. Exercise hemodynamics can provide surrogate information, and
invasive cardiopulmonary exercise testing can be used widely, as long as it is performed
and interpreted appropriately [33]. Certainly, to understand the effects of future pulmonary
arterial hypertension therapies, measurement of exercise hemodynamics, as a stand-alone
trial or a sub-study performed at expert centers, should form part of the evaluation of any
novel treatment. Re-establishment of the normal reserve of recruitable capillary surface
area in patients should be the objective of every pulmonary arterial hypertension therapy.
Author Contributions: Langleben and Orfanos contributed equally to this work. Conceptualization,
D.L., S.E.O., B.D.F., N.M., M.G. and J.D.C.; writing—original draft preparation, D.L., S.E.O. and J.D.C.;
writing—review and editing, D.L., S.E.O., B.D.F., N.M., M.G. and J.D.C. All authors have read and
agreed to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Acknowledgments: The authors thank Ioanna Korovesi for preparing Figure 1.
Conflicts of Interest: Langleben has served as a consultant, speaker and/or clinical investigator
for Acceleron, Bayer, Janssen, Merck, Phase-Bio and United Therapeutics. Orfanos has served as a
consultant, speaker and/or clinical investigator for ELPEN, Ferrer-Galenica, GSK, Janssen, MSD, and
United Therapeutics. Fox has served a consultant, speaker and/or clinical trial investigator for GSK,
Astra Zeneca, Boehringer Ingelheim, Zambon, Roche, Actelion and United Therapeutics. Messas has
no conflicts to declare. Giovinazzo has no conflicts to declare. Catravas has no conflicts to declare.

References
1.
2.
3.
4.
5.

6.

Hickam, J.B.; Cargill, W.H. Effect of exercise on cardiac output and pulmonary arterial pressure in normal persons and in patients
with cardiovascular disease and pulmonary emphysema. J. Clin. Investig. 1948, 27, 10–23. [CrossRef]
Granath, A.; Jonsson, B.; Trandell, T. Circulation in healthy old men, studied by right heart catheterization at rest and during
exercise in supine and sitting position. Acta Med. Scand. 1964, 176, 425–446. [CrossRef]
Kovacs, G.; Olschewski, A.; Berghold, A.; Olschewski, H. Pulmonary vascular resistances during exercise in normal subjects:
A systematic review. Eur. Respir. J. 2012, 39, 319–328. [CrossRef]
Naeije, R.; Vanderpool, R.; Dhakal, B.P.; Saggar, R.; Saggar, R.; Vachiery, J.L.; Lewis, G.D. Exercise-induced pulmonary hypertension: Physiological basis and methodological concerns. Am. J. Respir. Crit. Care Med. 2013, 187, 576–583. [CrossRef]
Wearn, J.T.; Ernstene, A.C.; Bromer, A.W.; Barr, J.S.; German, W.J.; Zschiesche, L.J. The normal behavior of the pulmonary blood
vessels with observations on the intermittence of the flow of blood in the arterioles and capillaries. Am. J. Physiol. 1934, 109,
236–256. [CrossRef]
Wagner, W.W., Jr. Pulmonary microcirculatory observations in vivo under physiological conditions. J. Appl. Physiol. 1969, 26,
375–377. [CrossRef]

J. Clin. Med. 2022, 11, 4568

7.
8.
9.

10.
11.
12.
13.

14.

15.

16.

17.
18.
19.

20.
21.

22.
23.
24.
25.

26.

27.
28.
29.
30.
31.

8 of 9

Presson, R.G., Jr.; Hanger, C.C.; Godbey, P.S.; Graham, J.A.; Lloyd, T.C., Jr.; Wagner, W.W., Jr. Effect of increasing flow on
distribution of pulmonary capillary transit times. J. Appl. Physiol. 1994, 76, 1701–1711. [CrossRef]
Kuebler, W.M. Real-time imaging assessment of pulmonary vascular responses. Proc. Am. Thorac. Soc. 2011, 8, 458–465. [CrossRef]
Catravas, J.D.; Orfanos, S.E. Pathophysiologic functions of endothelial angiotensin-converting enzyme. In Vascular Endothelium:
Physiology, Pathology and Therapeutic Opportunities; Born, G.V.R., Schwartz, C.J., Eds.; Schattauer: Stuttgart, Germany, 1997;
pp. 193–204.
Toivonen, H.J.; Catravas, J.D. Effects of blood flow on lung ACE kinetics: Evidence for microvascular recruitment. J. Appl. Physiol.
1991, 71, 2244–2254. [CrossRef]
Orfanos, S.E.; Ehrhart, I.C.; Barman, S.; Hofman, W.F.; Catravas, J.D. Endothelial ectoenzyme assays estimate perfused capillary
surface area in the dog lung. Microvasc. Res. 1997, 54, 145–155. [CrossRef]
Orfanos, S.E.; Langleben, D.; Khoury, J.; Schlesinger, R.D.; Dragatakis, L.; Roussos, C.; Ryan, J.W.; Catravas, J.D. Pulmonary
capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation 1999, 99, 1593–1599. [CrossRef]
Orfanos, S.E.; Armaganidis, A.; Glynos, C.; Psevdi, E.; Kaltsas, P.; Sarafidou, P.; Catravas, J.D.; Dafni, U.G.; Langleben, D.;
Roussos, C. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation
2000, 102, 2011–2018. [CrossRef]
Langleben, D.; Orfanos, S.E.; Giovinazzo, M.; Hirsch, A.; Baron, M.; Senecal, J.L.; Armaganidis, A.; Catravas, J.D. Pulmonary
capillary endothelial metabolic dysfunction: Severity in pulmonary arterial hypertension related to connective tissue disease
versus idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2008, 58, 1156–1164. [CrossRef]
Orfanos, S.E.; Psevdi, E.; Stratigis, N.; Langleben, D.; Catravas, J.D.; Kyriakidis, M.; Moutsopoulos, H.M.; Roussos, C.;
Vlachoyiannopoulos, P.G. Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis Rheum. 2001,
44, 902–911. [CrossRef]
Langleben, D.; Orfanos, S.E.; Giovinazzo, M.; Schlesinger, R.D.; Naeije, R.; Fox, B.D.; Abualsaud, A.O.; Blenkhorn, F.; Rudski, L.G.;
Catravas, J.D. Pulmonary capillary surface area in supine exercising humans: Demonstration of vascular recruitment. Am. J.
Physiol. Lung Cell Mol. Physiol. 2019, 317, L361–L368. [CrossRef]
Langleben, D.; Fox, B.D.; Orfanos, S.E.; Giovinazzo, M.; Catravas, J.D. Pulmonary capillary recruitment and distention in
mammalian lungs: Species similarities. Eur. Respir. Rev. 2022, 31, 210248. [CrossRef]
Hassoun, P.M. Pulmonary Arterial Hypertension. N. Engl. J. Med. 2021, 385, 2361–2376. [CrossRef]
Humbert, M.; Guignabert, C.; Bonnet, S.; Dorfmuller, P.; Klinger, J.R.; Nicolls, M.R.; Olschewski, A.J.; Pullamsetti, S.S.;
Schermuly, R.T.; Stenmark, K.R.; et al. Pathology and pathobiology of pulmonary hypertension: State of the art and research
perspectives. Eur. Respir. J. 2019, 53, 1801887. [CrossRef]
Galie, N.; Channick, R.N.; Frantz, R.P.; Grunig, E.; Jing, Z.C.; Moiseeva, O.; Preston, I.R.; Pulido, T.; Safdar, Z.; Tamura, Y.; et al.
Risk stratification and medical therapy of pulmonary arterial hypertension. Eur. Respir. J. 2019, 53, 1801889. [CrossRef]
Harel, F.; Langleben, D.; Provencher, S.; Fournier, A.; Finnerty, V.; Nguyen, Q.T.; Letourneau, M.; Levac, X.; Abikhzer, G.;
Guimond, J.; et al. Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: A phase II
safety and proof of principle trial. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1136–1144. [CrossRef]
Humbert, M.; Sitbon, O.; Simonneau, G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2004, 351, 1425–1431.
[CrossRef] [PubMed]
Rich, S.; Pogoriler, J.; Husain, A.N.; Toth, P.T.; Gomberg-Maitland, M.; Archer, S.L. Long-term effects of epoprostenol on the
pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010, 138, 1234–1239. [CrossRef] [PubMed]
Sugiyama, Y.; Matsubara, H.; Shimokawahara, H.; Ogawa, A. Outcome of mean pulmonary arterial pressure-based intensive
treatment for patients with pulmonary arterial hypertension. J. Cardiol. 2022, in press. [CrossRef] [PubMed]
D’Alto, M.; Badagliacca, R.; Lo Giudice, F.; Argiento, P.; Casu, G.; Corda, M.; Correale, M.; Ghio, S.; Greco, A.; Lattanzio, M.; et al.
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentantadalafil in pulmonary arterial hypertension.
J. Heart Lung Transplant. 2020, 39, 1389–1397. [CrossRef] [PubMed]
Badagliacca, R.; D’Alto, M.; Ghio, S.; Argiento, P.; Bellomo, V.; Brunetti, N.D.; Casu, G.; Confalonieri, M.; Corda, M.;
Correale, M.; et al. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 2021, 203, 484–492. [CrossRef]
Sniderman, A.D.; Fitchett, D.H. Vasodilators and pulmonary arterial hypertension: The paradox of therapeutic success and
clinical failure. Int. J. Cardiol 1988, 20, 173–181. [CrossRef]
Rich, S.; Martinez, J.; Lam, W.; Levy, P.S.; Rosen, K.M. Reassessment of the effects of vasodilator drugs in primary pulmonary
hypertension: Guidelines for determining a pulmonary vasodilator response. Am. Heart J. 1983, 105, 119–127. [CrossRef]
Renard, S.; Paulin, R.; Breuils-Bonnet, S.; Simard, S.; Pibarot, P.; Bonnet, S.; Provencher, S. Pim-1: A new biomarker in pulmonary
arterial hypertension. Pulm. Circ. 2013, 3, 74–81. [CrossRef]
Hemnes, A.R.; Trammell, A.W.; Archer, S.L.; Rich, S.; Yu, C.; Nian, H.; Penner, N.; Funke, M.; Wheeler, L.; Robbins, I.M.; et al.
Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 2015, 131, 401–409. [CrossRef]
Hemnes, A.R.; Zhao, M.; West, J.; Newman, J.H.; Rich, S.; Archer, S.L.; Robbins, I.M.; Blackwell, T.S.; Cogan, J.; Loyd, J.E.; et al.
Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care
Med. 2016, 194, 464–475. [CrossRef]

J. Clin. Med. 2022, 11, 4568

32.

33.
34.
35.
36.

37.

38.
39.
40.

41.
42.

43.

9 of 9

Langleben, D.; Orfanos, S.E.; Giovinazzo, M.; Schlesinger, R.D.; Hirsch, A.M.; Blenkhorn, F.; Lesenko, L.; Armaganidis, A.;
Catravas, J.D. Acute vasodilator responsiveness and microvascular recruitment in idiopathic pulmonary arterial hypertension.
Ann. Intern. Med. 2015, 162, 154–156. [CrossRef] [PubMed]
Maron, B.A.; Cockrill, B.A.; Waxman, A.B.; Systrom, D.M. The invasive cardiopulmonary exercise test. Circulation 2013, 127,
1157–1164. [CrossRef] [PubMed]
Singh, I.; Oliveira, R.K.F.; Naeije, R.; Rahaghi, F.N.; Oldham, W.M.; Systrom, D.M.; Waxman, A.B. Pulmonary Vascular Distensibility and Early Pulmonary Vascular Remodeling in Pulmonary Hypertension. Chest 2019, 156, 724–732. [CrossRef] [PubMed]
Systrom, D.; Warren, A.; Naeije, R. The Role of Exercise Testing in Pulmonary Vascular Disease: Diagnosis and Management. Clin.
Chest Med. 2021, 42, 113–123. [CrossRef] [PubMed]
Kovacs, G.; Herve, P.; Barbera, J.A.; Chaouat, A.; Chemla, D.; Condliffe, R.; Garcia, G.; Grunig, E.; Howard, L.; Humbert, M.; et al.
An official European Respiratory Society statement: Pulmonary haemodynamics during exercise. Eur. Respir. J. 2017, 50, 1700578.
[CrossRef]
Zeder, K.; Banfi, C.; Steinrisser-Allex, G.; Maron, B.A.; Humbert, M.; Lewis, G.D.; Berghold, A.; Olschewski, H.; Kovacs, G.
Diagnostic, prognostic and differential-diagnostic relevance of pulmonary hemodynamics during exercise—A systematic review.
Eur. Respir. J. 2022, in press. [CrossRef]
Valle, F.H.; Esfandiari, S.; Jang, H.J.; Fuchs, F.C.; Wright, S.P.; Granton, J.; Mak, S. Contrasting haemodynamic effects of exercise
and saline infusion in older adults with pulmonary arterial hypertension. ERJ Open Res. 2021, 7, 00183. [CrossRef]
Sommer, N.; Ghofrani, H.A.; Pak, O.; Bonnet, S.; Provencher, S.; Sitbon, O.; Rosenkranz, S.; Hoeper, M.M.; Kiely, D.G. Current and
future treatments of pulmonary arterial hypertension. Br. J. Pharmacol. 2021, 178, 6–30. [CrossRef]
Humbert, M.; McLaughlin, V.; Gibbs, J.S.R.; Gomberg-Maitland, M.; Hoeper, M.M.; Preston, I.R.; Souza, R.; Waxman, A.; Escribano
Subias, P.; Feldman, J.; et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N. Engl. J. Med. 2021, 384,
1204–1215. [CrossRef]
Zolty, R. Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension. J. Exp. Pharmacol. 2021, 13, 817–857.
[CrossRef]
Hoeper, M.M.; Barst, R.J.; Bourge, R.C.; Feldman, J.; Frost, A.E.; Galie, N.; Gomez-Sanchez, M.A.; Grimminger, F.; Grunig, E.;
Hassoun, P.M.; et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized
IMPRES study. Circulation 2013, 127, 1128–1138. [CrossRef] [PubMed]
Maron, B.A.; Brittain, E.L.; Hess, E.; Waldo, S.W.; Baron, A.E.; Huang, S.; Goldstein, R.H.; Assad, T.; Wertheim, B.M.;
Alba, G.A.; et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: A retrospective
cohort study. Lancet Respir. Med. 2020, 8, 873–884. [CrossRef]

